DFCM
KLRS

Dark Forest Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Dark Forest Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Hold
0
– – – 1539
2022
Q3 		– Hold
0
– – – 1491
2022
Q1 		– Sell
-752
Closed -$224K – 1840
2021
Q4 		$224K Buy
752
+540
+255% +$251K 0.08% 209
2021
Q3 		$122K Buy
+212
New +$98.2K 0.04% 337

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dark Forest Capital Management's KLRS Position: Q4 2022 in Review

Dark Forest Capital Management held its Kalaris Therapeutics (KLRS) position steady in Q4 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Dark Forest Capital Management first reported a position in KLRS in Q3 2021 and has held it in 2 quarters since. The position peaked at $224K in Q4 2021. 85 funds tracked by Wall St. Rank hold KLRS as of Q4 2022.

  • Dark Forest Capital Management held 0 shares of Kalaris Therapeutics worth $0 as of Q4 2022.
  • Dark Forest Capital Management left its Kalaris Therapeutics share count unchanged in Q4 2022.
  • Kalaris Therapeutics made up ﹤0.01% of Dark Forest Capital Management's portfolio in Q4 2022, its #1539 holding.
  • Dark Forest Capital Management first reported a position in Kalaris Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • Dark Forest Capital Management's Kalaris Therapeutics position peaked at $224K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2022.

Based on Dark Forest Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.